HEALTH MANAGEMENT. Marshall of Edwards Announces start of phase I clinical trial with lead oncology drug candidate ME-143

Marshall of Edwards, Inc. (NASDAQ: MSHL), the clinical development of novel therapeutics for cancer metabolism, oncology company has today announced the initiation of a phase I clinical trial of the company's drug candidates ME-143 in patients with solid tumors carry fireproof. The study is in collaboration with the Sarah Cannon Research Institute in Nashville, Tennessee, after the adoption of the investigational application administration (FDA) last month is carried out new drug (IND) by the U.S. food and drug.
The phase I dose escalation study evaluates the safety and tolerability of intravenous ME-143 fireproof in patients with solid tumors. In addition, the study is to characterize the pharmacokinetic profile of intravenous ME-143 and describe each preliminary clinical tumor activity observed. The open-label study is to register expected to up to 24 patients with data collected final by in the second half of 2012.
"We are pleased to begin treating patients with ME-143, a promising drug candidate, the anti-tumor activity in pre-clinical studies demonstrated", Robert D. said mass, MD, Chief Medical Officer of Marshall of Edwards. "Together with the Sarah Cannon Research Institute, we are important information on dosage, safety and potential effectiveness of intravenous ME-143 in the coming months, inform the design of our randomized clinical phase II trials in combination with standard of care chemotherapy obtain."
About ME-143
ME-143 is the lead oncology drug candidates by Marshall Edwards' NADH oxidase inhibitor program. It comes from a proprietary isoflavones technology platform that has generated a number of connections with Anti-proliferative activity against cancer cells in laboratory studies. In pre-clinical studies, ME-143 strong activity has shown against a number of tumor cell lines, including breast cancer, colorectal and ovarian cancer. In addition to the wide single-agent activity, ME-143 has shown an ability to the cytotoxic effects of chemotherapy in pre-clinical studies. Marshall of Edwards has exclusive worldwide rights to ME-143. ME-143 was is an investigational drug and not by the FDA for commercial distribution in the United States or other countries.

Posted in: Announces,candidate,clinical,Edwards,Marshall,ME143,oncology,phase,start,trial